A fragmentable MHC class I protein platform that reveals T cell epitope leads defined by both binding and stability the next morning —so promising programs start with a stronger signal.
T cell epitope LEAD discovery, redefined
Find the leads that endure while you sleep
The missing dimension in more accurate epitope selection is already in the complex.
You didn't come this far to stop
Shorten clinical development with greater confidence.
Cell-free Precision
Targeting HLA molecules without patients' samples
Intelligent Simplicity
Load in a tube, wait overnight and protein gel electrophoresis
Next-Gen Discovery
Identify epitope leads that escape binding prediction
At Otter Bio, we focus on discovering novel antigens that amplify cancer visibility, revolutionizing cancer treatment through advanced immunology.
Many T cell epitope lead screens stop at whether a peptide can bind MHC class I. But transient binding alone can leave teams chasing leads that do not hold the signal long enough to matter.
The gap in the signaL
Binding is a start.
Stability is the proof.
We add the dimension of complex stability
Not just another MHC class I peptide predictor. Redefining new T cell epitopes based on temporal stability.
OUR APPROACH
Our fragmentable major histocompatibility class I protein is designed to make stability measurable the next morning using traditional protein gel—without adding complexity to the workflow.
Mimicking cellular peptide MHC class I complex stability in a tube
From signal
to impact.
A stronger first signal can change the path of an entire program.
Where IT can Go
Let's find the
next signal.
start a conversation
Interested in exploring a partnership, a collaboration, or a new application for the platform? We’d love to hear what you’re working on.
Partnership & scientific collaborations
